Turmeric and Curcumin on Sebum Production
Atslēgvārdi
Abstrakts
Apraksts
Turmeric extracts and curcumin have been shown to be safe, even at high doses without significant side-effects. Previous clinical studies in other inflammatory skin diseases have shown that a dosage of curcumin at 6,000 mg daily was effective while lower doses were not. In a human phase I clinical trial examining the effects of high dose curcumin in preventing premalignant lesions, even curcumin doses as high as 8,000 mg/day resulted in no toxic effects after 3 months. This study will involve participant ingestion of 6,000 mg/day of turmeric or curcumin to assess how this affects their sebum production.
The investigators will also be collecting stool from the study subjects, and examining how the curcumin and turmeric may modulate their gut microbiome. The investigators will specifically be looking to see if curcumin or turmeric have any changes on the gut flora towards bacteria that produce more short chain fatty acids. Certain bacteria that make up the microbiome produce short chain fatty acids, such as butyrate and propionate, which have demonstrated anti-inflammatory properties. Thus, it would be interesting to see if turmeric or curcumin exert any of its anti-inflammatory effects via modulation of the microbiome.
Datumi
| Pēdējoreiz pārbaudīts: | 11/30/2018 |
| Pirmais iesniegtais: | 10/31/2016 |
| Paredzētā reģistrācija iesniegta: | 02/22/2017 |
| Pirmais izlikts: | 02/27/2017 |
| Pēdējais atjauninājums iesniegts: | 12/17/2018 |
| Pēdējā atjaunināšana ievietota: | 12/18/2018 |
| Faktiskais studiju sākuma datums: | 11/29/2016 |
| Paredzamais primārās pabeigšanas datums: | 08/27/2017 |
| Paredzamais pētījuma pabeigšanas datums: | 08/27/2017 |
Stāvoklis vai slimība
Iejaukšanās / ārstēšana
Dietary Supplement: Turmeric group
Dietary Supplement: Curcumin Group
Dietary Supplement: Placebo Group
Fāze
Roku grupas
| Roka | Iejaukšanās / ārstēšana |
|---|---|
| Active Comparator: Turmeric group Turmeric Tablets:
Each tablet contains 1,000 mg of Turmeric (Curcuma Longa) per tablet. Dose: subjects will take 6 tablets per day, with a total daily dose of 6,000 mg.
Supplied by Sabinsa Corporation | Dietary Supplement: Turmeric group |
| Active Comparator: Curcumin Group Curcumin and Bioperine tablets:
Each tablet contains 1,000mg Curcumin + 1.25mg black pepper. Dose: subjects will take 6 tablets per day, with a total dose of 6,000mg curcumin.
Supplied by Sabinsa corporation | Dietary Supplement: Curcumin Group |
| Placebo Comparator: Placebo Group Placebo tablets made to look like the turmeric and curcumin tablets
Each placebo tablet will contain: microcrystalline cellulose, dicalcium phosphate, PVPK30, sodium starch glycolate, magnesium stearate, OpaDry orange coating.
Dose: subjects in this group will take 6 placebo tablets per day | Dietary Supplement: Placebo Group |
Atbilstības kritēriji
| Vecums, kas piemērots studijām | 18 Years Uz 18 Years |
| Dzimumi, kas ir piemēroti studijām | All |
| Pieņem veselīgus brīvprātīgos | Jā |
| Kritēriji | Inclusion Criteria: 1. Age 18 to 50 years of age, and 2. Subject must be able to read and comprehend study procedures and consent forms. Exclusion Criteria: 1. Subject should be generally healthy and have no smoking history in the past one year, and must have no history of diabetes, metabolic syndrome, known cardiovascular disease, malignancy, kidney disease, or chronic steroid use. 2. Those who used topical medications in the past two weeks or systemic antibiotics or oral probiotics within one month of starting the study. 3. Subjects who are postmenopausal 4. Those who are pregnant or breastfeeding. 5. Those that are prisoners or cognitively impaired. 6. Those who have a known allergy to black pepper should not participate in this clinical trial, since one of the treatments consists of tablets containing a small amount (1.25mg/tablet) of black pepper. 7. Those that are taking angiotensin converting enzyme inhibitor medications or angiotensin receptor blocker medications for any reason. |
Rezultāts
Primārie rezultāti
1. Sebum production [8 weeks]
Sekundārie iznākuma mērījumi
1. Change from Baseline in Sebum profile, such as inflammatory markers at 8 weeks [8 weeks]
2. Change in stool microbiome diversity (optional collections for subjects) from baseline at 8 weeks [8 weeks]
